CG Oncology (CGON) Director Leonard E Post Sells $62K of Stock

By TradeTexts Research Desk Oct 19, 2026, 5:02 PM EDT

Key Points

Director Leonard E Post sold 1,000 shares of CG Oncology, Inc. (NasdaqGS: CGON) at $62.06 per share on October 15, 2026, under a pre-arranged trading plan.
The biotechnology firm recently reported trailing twelve-month revenue of $6,228,000 and negative earnings per share of $2.69.
Major investment firms including T. Rowe Price and Rtw Investments previously adjusted large positions in the clinical-stage biotech company.

Since the trade, $CGON is down 3.1% to date (from the $61.86 close on Oct 15, 2026).

Get CG Oncology text alerts

We text you when insiders, Congress, analysts or big funds move on $CGON.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated CG Oncology, Inc. alert may contain errors. Disclosures

CG Oncology, Inc. (NasdaqGS: CGON) Director Leonard E Post sold 1,000 shares of the company on October 15, 2026. The transaction was disclosed in a Form 4 filed with the Securities and Exchange Commission.

CGON CG Oncology, Inc.

$59.96 +43.48% year to date

Daily close · Oct 19, 2026

Inside Leonard E Post's CG Oncology Trade

Post sold the shares at a price of $62.06 each, totaling $62,065. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Post owns zero shares of CG Oncology, cutting his direct stake by 100%. The stock closed at $61.86 on the day of the trade.

Other Institutional Activity in CG Oncology

Large institutional investors have made notable adjustments to their holdings in the firm. T. Rowe Price Investment Management grew its holdings by 6,297,797 shares, ending with 6,720,389 shares worth about $477,483,658. Rtw Investments boosted its position by 4,972,681 shares, finishing with 6,984,808 shares valued at approximately $496,270,629. Farallon Capital Management also expanded its stake significantly, adding 666,000 shares to hold 674,000 shares worth about $47,887,702.

CG Oncology, Inc. Stock Down 19.6%

CG Oncology shares recently traded around $59.96 as of October 19, 2026, sitting about 3.1% below their $61.86 close on the transaction date.

Recent Earnings

CG Oncology posted trailing twelve-month revenue of $6,228,000 and basic earnings per share of negative $2.69. The late-stage clinical biopharmaceutical company recorded a return on equity of negative 26.4%. Investors await the next financial update when the company releases earnings on November 9, 2026.

Insider Buying and Selling at CG Oncology, Inc.

Insiders have executed several sales over recent months. Post previously sold 1,000 shares on September 15, 2026, at $72.98 each, and another 1,000 shares on August 14, 2026, at $74.54 each. Fellow director James J. Mulay also sold 24,165 shares at $75.16 on July 10, 2026.

Analysts Set New Price Targets

Wall Street firms have maintained positive outlooks on the stock. RBC Capital maintained an Outperform rating with a $79.00 price target on August 7, 2026. Piper Sandler maintained an Overweight rating and raised its target to $85.00 on the same day.

About CG Oncology

CG Oncology, Inc. is a Dallas-based clinical-stage biopharmaceutical company focused on developing therapies for bladder cancer patients. Its lead candidate, cretostimogene grenadenorepvec, is designed to treat various stages of the disease.

Bottom Line

Post's complete exit through his planned sale reduces his direct involvement as a director holds zero shares. Market participants will watch the upcoming November 9 earnings report for updates on the company's clinical pipeline.